LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer

Exclusion Criteria

• •Prior treatment with any immunotherapy, including CART therapy, tumor vaccine therapy, radium-223, checkpoint inhibitors.
• •Prior treatment with any PSMA targeting therapy.
• •Subjects with severe mental disorders.
• •Subjects with severe cardiovascular diseases: a, New York Heart Association (NYHA) stage III or IV congestive heart failure; b, history of myocardial infarction or coronary artery bypass grafting (CABG) within 6 months; c, clinical significance of ventricular arrhythmia, or history of unexplained syncope, non-vasovagal or dehydration; d, history of severe non-ischemic cardiomyopathy; e, the left ventricular ejection fraction (LVEF \< 55%) was decreased by echocardiography or MUGA scan (within 8 weeks before PBMC collection), and abnormal interventricular septal thickness and atrioventricular size associated with myocardial amyloidosis.
• •Patients with ongoing or active infection.
• •Aspartate aminotransferase or Alanine aminotransferase \>2.5\*ULN; CK\>1.5\*ULN; CK-MB\>1.5\*ULN; TnT\>1.5\*ULN.
• •Total bilirubin \>1.5\*ULN.
• •Partial prothrombin time or activated partial thromboplastin time or international standardized ratio \> 1.5\*ULN without anticoagulant treatment.
• •History of participation in other clinical studies within 3 months or treatment with any gene therapy product.
• •Intolerant or allergic to cyclophosphamide or fludarabine.
• •Subjects not appropriate to participate in this clinical study judged by investigators.